Investigation of Thromboembolic Events in COVID-19 Infected Patients
Öz
Aim: In this study, we sought to determine patient characteristics and clinical outcomes of patients who experience this complication, as well as the frequency of thromboembolic events (TEE) in COVID-19 patients hospitalized.
Materials and Methods: Between January 2020 and December 2021, all the patients with positive COVID-19 PCR test results were enrolled in this study. The data of the cases that developed TEE with the diagnosis of COVID-19 were evaluated retrospectively.
Results:During this time, 2,845 inpatients were admitted with COVID-19. Among this group, 96 patients (3.37%) had COVID-19 - related TEE. The mean age was 63.76±13.85 years (range, 28–80 years) with 46 men (47.92%) and 50 women (52.08%). Of the patients, 46 of 96 (47.92%) had severe COVID-19, and 50 of 96 (52.08%) had only mild respiratory symptoms. Severe COVID-19 group patients were older but there was not statistically significance between the groups. Peripheral venous disease was more common in mild COVID-19 group, while peripheral arterial disease is more common in severe COVID-19 group.CRP, uric acid, troponin, creatinine,D-dimer and leukocyte levels were higher in severe COVID-19 patients with TEE (p<0.05). Peripheral venous disease was present in 81 of 96 (84.37%), peripheral arterial disease in 5 of 96 (5.2%), and pulmonary embolism in 11 (11.45%) cases. One patient (1.04%) had both peripheral venous disease and pulmonary embolism. The overall mortality was 6.25% (6/96).
Conclusion: COVID-19-associated thrombotic process affects more frequently veins than arteries. Given the significant observed risk for TEE in COVID-19, diagnostic imaging for TEE should be evaluated with a high degree of clinical suspicion.
Anahtar Kelimeler
Kaynakça
- Vo TD, Daoud A, Jeney A, Andacheh I, Behseresht J, Hsu J,et al. COVID-19-related Peripheral Arterial Thrombosis Treated in a Large Health Maintenance Organization. Ann Vasc Surg. 2022;84:6-11.
- Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020; 20:389.
- Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020; 46:1089.
- Abou Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res. 2020;194:101-15.
- Miesbach W, Makris M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clin Appl Thromb Hemost. 2020;26.
- Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12:570.
- Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping review. Thromb Res. 2020;192:152–60.
- Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 2020;395(10223):497–506.
- Danzi G B, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41(19):1858
- Chen N, Zhou M, Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet.2020;395(10223):507–13.